Open AccessCombination targeted pulmonary hypertension therapy in the resolution of Dasatinib‐associated pulmonary arterial hypertension
Author(s) -
Jose Arun,
Rafei Hind,
Ahari Jalil
Publication year - 2017
Publication title -
pulmonary circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.791
H-Index - 40
ISSN - 2045-8940
DOI - 10.1177/2045893217716659
Subject(s) - medicine , dasatinib , pulmonary hypertension , tyrosine kinase inhibitor , cardiology , combination therapy , hemodynamics , endothelin receptor , myeloid leukemia , pharmacology , imatinib , receptor , cancer
Dasatinib is a small‐molecule tyrosine kinase inhibitor used in the treatment of hematological malignancies. Pulmonary arterial hypertension (PAH) is a rare but known complication. The mainstay of treatment is cessation of Dasatinib, and while clinical improvement is rapid, complete hemodynamic resolution of pulmonary hypertension (PH) still remains exceedingly uncommon. We present a case of Dasatinib‐induced PAH in a woman with chronic myeloid leukemia, who demonstrated rapid and complete clinical and hemodynamic resolution following treatment with combination pulmonary vasodilator therapy using an endothelin receptor antagonist and a phosphodiesterase‐5 inhibitor. This case suggests there may be an association between the use of targeted PH medication in combination and the complete resolution of dasatinib‐associated PAH, but further investigation is required.